Lifetrack Newsletter

Cyplasin-SC TM Kills Melanoma Cells, Even Derived From Different Patients but Leaves Normal Human Cells Unharmed

Edmonton—It is well known that many cancer types – or even the same cancer in different patients – show different sensitivities to a given therapeutic treatment. In earlier studies Cyplasin-SCTM has shown to be an efficient killer of many cancer cell types whereas normal human cells were left intact. An independent third party study conducted by Professor di Liegro, Department of Medicine of the University of Palermo, Italy, tested Cyplasin-SCTM on 5 melanoma cell lines derived from 5 different patients to determine if all melanoma cells were equally susceptible to Cyplasin-SCTM or if there were specific melanomas that did not respond to the drug. As a control to these experiments normal human cells were also exposed to the same concentrations of Cyplasin-SCTM used for the melanoma experiments.

The results presented unequivocal evidence that all melanoma cell types studied were killed by Cyplasin-SCTM whereas even at the highest concentrations of Cyplasin-SCTM used in these experiments normal human cells remained unaffected. However, within this group of five different human melanomas, two were detected that required almost two times the dose that was sufficient to kill other melanomas. This corresponds exactly to the situation “in real life” where one patient reacts to low concentration of a given drug whereas others require higher doses for the same therapeutic effect. Yet, even such high doses were not harmful to normal human cells.

These results confirm convincingly the usefulness of Cyplasin-SCTM as a treatment of melanoma. The required concentrations for killing the individual tumor can be efficiently optimized without harming normal cells, or in other words, the concentration window for individual therapy is large and separated enough from a concentration that may harm normal cells. These results will now be transferred to animal dose ranging studies and continue on to actual tumor-bearing animals.

About Melanoma
Market statistics for skin cancer and melanoma show that melanoma currently affects more then 2.4 million people worldwide. In the US more than 62,000 new cases are reported every year, as fair-skinned and sunbelt populations are at high risk for the disease.Australia has the highest rate of melanoma in the world among males and has the second highest rate in the world among females (Australia’s Health 2004, AIHW). Overall the world wide incidence has doubled over the past 20 years.

About Cyplasin-SC™
Cyplasin-SC™ has demonstrateda selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as a potential anti- cancer therapeutic product. Patents have been issued to the Company covering the Cyplasin protein.

About Cyplasin Biomedical Ltd. (CBL)
Foundedin 2007 and headquartered in Edmonton, Canada witharesearch laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company’s current goal isto develop and commercialize the anticancer properties of Cyplasin-SC TM. CBL is publicly traded (CYPL:OTCBB)

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

The OTCBB Exchange has neither approved nor disapproved of the information contained herein.

For information contact:

Source: BioAlberta.com